NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Today's Medical & Research News



Biotechnology Business


Studies in the area of biotechnology business reported from ImmunoGen, Inc.



November 7th, 2009




Related Topics
United States
Waltham
Analytical Chemistry
Biotechnology Business
Biotechnology Company
ImmunoGen
Pharmaceutical Sciences
Pharmaceuticals
Therapy
Treatment
ImmunoGen Inc
According to a study from the United States, "The U.S. and European Pharmacopeias require subvisible (>= 10 and >= 25 mu m) and visible particulate testing of therapeutics to ensure their safety and suitability for clinical use. The objective of this article is to compare the sizing and counting accuracies of light obscuration, which is the standard technique used to measure subvisible particulate matter, and Micro-Flow Imaging (MFI ™), a new imaging-based technology."

"An immunoconjugate was selected as the model protein for this study since it could be induced to form particulate matter in PBS. Light obscuration was performed as described in USP chapter < 788 > while MFI measurements were conducted per the manufacturer's procedures. The two techniques yielded similar results when polystyrene standards were analyzed. However, the MFI measurements indicated the presence of significantly more particles in the protein-containing solution compared to the light obscuration measurements. The presence of nonspherical protein particles as well as particles that possess a refractive index similar to the solvent that they are in appear to be detected by MFI, but not by light obscuration, leading to the difference in the results," wrote C.T. Huang and colleagues, ImmunoGen, Inc.

The researchers concluded: "Imaging-based technologies could aid in developing formulations and processes that would minimize the formation of protein particulates."

Huang and colleagues published their study in the Journal of Pharmaceutical Sciences (Quantitation of Protein Particles in Parenteral Solutions Using Micro-Flow Imaging. Journal of Pharmaceutical Sciences, 2009;98(9):3058-3071).

For more information, contact R. Krishnamurthy, ImmunoGeneral Inc., 830 Winter St., Waltham, MA 02451, USA.

Publisher contact information for the Journal of Pharmaceutical Sciences is: John Wiley & Sons Inc., 111 River St., Hoboken, NJ 07030, USA.

Keywords: United States, Waltham, Analytical Chemistry, Biotechnology Business, Biotechnology Company, ImmunoGen, Pharmaceutical Sciences, Pharmaceuticals, Therapy, Treatment, ImmunoGen, Inc.

This article was prepared by NewsRx editors from staff and other reports. Copyright 2009, NewsRx.com.

NewsRx Passes
Advertisement
------------------------
Security by Verisign PR Login